This section highlights FDA-related milestones and regulatory updates for drugs developed by Teva Pharmaceutical Industries (TEVA).
Over the past two years, Teva Pharmaceutical Industries has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
PONLIMSI, TEV-749, duvakitug, teriparatide, AUSTEDO, Saxenda, and AJOVY. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
PONLIMSI FDA Regulatory Events
PONLIMSI is a drug developed by Teva Pharmaceutical Industries for the following indication: for Biosimilar Candidate to Xolair® (omalizumab).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- PONLIMSI
- Announced Date:
- March 30, 2026
- Indication:
- for Biosimilar Candidate to Xolair® (omalizumab)
Announcement
Teva Pharmaceutical Industries Ltd The United States (U.S.) Food and Drug Administration (FDA) has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia®, and Teva's applications for a proposed biosimilar candidate to Xolair® (omalizumab) have been accepted by both the U.S. FDA and the European Medicines Agency (EMA).
AI Summary
The U.S. Food and Drug Administration has approved PONLIMSI (denosumab‑adet) as a biosimilar to Prolia®. PONLIMSI is intended to treat postmenopausal women with osteoporosis at high risk for fracture and to increase bone mass in men at high risk, including men on androgen deprivation therapy for prostate cancer and women receiving aromatase inhibitors for breast cancer. The approval offers clinicians and patients an additional denosumab option to help reduce vertebral, nonvertebral, and hip fractures.
Teva also announced that its applications for a proposed biosimilar to Xolair® (omalizumab) have been accepted for review by both the U.S. FDA and the European Medicines Agency (EMA). These acceptances advance Teva’s global biosimilars program and, if approved, could broaden access to biologic treatments for conditions driven by IgE, such as chronic spontaneous urticaria and certain allergic diseases.
Read Announcement
TEV-749 FDA Regulatory Timeline and Events
TEV-749 is a drug developed by Teva Pharmaceutical Industries for the following indication: In adult patients with schizophrenia.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- TEV-749
- Announced Date:
- February 20, 2026
- Indication:
- In adult patients with schizophrenia
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults.
AI Summary
Teva Pharmaceuticals’ U.S. affiliate announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) for TEV-’749, an extended-release injectable suspension of olanzapine for the treatment of schizophrenia in adults. TEV-’749 is an investigational, once-monthly subcutaneous long-acting injectable (LAI) formulation of the atypical antipsychotic olanzapine and is not approved by any regulatory authority at this time.
The NDA submission is supported by Phase 3 SOLARIS trial data, including Week 56 results in participants aged 18 to 64, showing efficacy, safety, and tolerability consistent with currently available olanzapine formulations. TEV-’749 uses SteadyTeq™, a proprietary copolymer technology from Medincell designed to provide a controlled, steady, sustained release of olanzapine. Regulatory review will determine whether the product can be approved for adult schizophrenia treatment.
Read Announcement- Drug:
- TEV-749
- Announced Date:
- December 9, 2025
- Indication:
- In adult patients with schizophrenia
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults.
AI Summary
Teva Pharmaceuticals announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for olanzapine extended‑release injectable suspension (TEV‑'749) to treat schizophrenia in adults. The filing is based on Phase 3 SOLARIS trial data, including Week 56 results in participants aged 18 to 64, which showed efficacy, safety and tolerability across a broad adult population. Olanzapine LAI remains investigational and is not approved for use.
Olanzapine LAI is a once‑monthly subcutaneous formulation designed to offer olanzapine’s therapeutic effects while supporting real‑world adherence and clinical stability. The product uses SteadyTeq™, a copolymer technology from Medincell, to provide controlled, sustained drug release. Teva said it will work with the FDA during the review and aims to advance this long‑acting injectable as part of its LAI treatment portfolio.
Read Announcement- Drug:
- TEV-749
- Announced Date:
- September 20, 2025
- Indication:
- In adult patients with schizophrenia
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 trial showing no incidence of post-injection delirium/sedation syndrome (PDSS) in study participants taking olanzapine LAI (TEV-'749), a once-monthly, long-acting injectable (LAI) subcutaneous formulation of olanzapine.1
AI Summary
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., presented 10 posters at the 2025 Psych Congress Annual Meeting showcasing its schizophrenia medicine pipeline, notably the complete SOLARIS Phase 3 trial of olanzapine LAI (TEV-’749).
This once-monthly, subcutaneous, long-acting injectable formulation demonstrated no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events through Week 56 in 3,470 injections. Its systemic safety profile matched known second-generation antipsychotic effects, with most treatment-emergent adverse events mild to moderate, including weight increase (36%), injection site reactions, and somnolence (7%).
Long-term effectiveness results showed stable symptom reduction (mean PANSS change –7.2) and functional improvement (mean PSP increase 4.6). Olanzapine LAI (TEV-’749) uses SteadyTeq™, a copolymer technology for controlled release. Investigators believe these data support TEV-’749 as the first long-acting olanzapine option to address adherence challenges and fill a critical gap in schizophrenia treatment.
Read Announcement- Drug:
- TEV-749
- Announced Date:
- March 31, 2025
- Indication:
- In adult patients with schizophrenia
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749.
AI Summary
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., presented a survey study examining attitudes and experiences from both patients and healthcare professionals (HCPs) regarding TEV-'749. This study complements the successful Phase 3 SOLARIS trial of the subcutaneous olanzapine extended-release injection. The survey revealed that over 92% of patients, along with 87% of nurses and 72% of physicians, were satisfied or very satisfied with the treatment regimen, including the initiation process, monthly dosing schedule, and overall drug experience. The findings highlight a strong preference for the subcutaneous injection format, with many participants favoring features such as a simplified initiation regimen and the absence of a lengthy post-injection monitoring period. These results underscore Teva’s commitment to developing innovative treatment options that address key challenges faced by individuals living with schizophrenia.
Read Announcement- Drug:
- TEV-749
- Announced Date:
- September 21, 2024
- Indication:
- In adult patients with schizophrenia
Announcement
Teva Pharmaceuticals, announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.
AI Summary
Teva Pharmaceuticals announced positive results from the Phase 3 SOLARIS trial evaluating TEV-‘749, a new subcutaneous extended-release olanzapine injection for adults with schizophrenia. The study met its primary endpoint by showing significant improvements in the Positive and Negative Syndrome Scale (PANSS) score from baseline to week 8. Key secondary endpoints also showed improvements as measured by the Clinical Global Impression-Severity (CGI-S) and Personal and Social Performance (PSP) scales. Researchers highlighted that, unlike existing long-acting olanzapine treatments, TEV-‘749 exhibited no cases of post-injection delirium/sedation syndrome (PDSS) in study participants, addressing a major safety concern associated with current options. These promising results suggest that TEV-‘749 could offer an effective and safer alternative for managing schizophrenia symptoms while eliminating the PDSS risk inherent in other long-acting olanzapine products.
Read Announcement
Duvakitug FDA Regulatory Timeline and Events
Duvakitug is a drug developed by Teva Pharmaceutical Industries for the following indication: for the treatment of moderate-to-severe inflammatory bowel disease (IBD).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- duvakitug
- Announced Date:
- February 17, 2026
- Indication:
- for the treatment of moderate-to-severe inflammatory bowel disease (IBD).
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd and Sanofi announced positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug, an investigational human monoclonal antibody targeting TL1A, which showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients with ulcerative colitis (UC) and Crohn's disease (CD) that initially responded to the induction phase.
AI Summary
Teva’s U.S. affiliate and Sanofi reported positive results from the RELIEVE UCCD long‑term extension study of duvakitug, an investigational human monoclonal antibody that targets TL1A. In 130 patients with ulcerative colitis or Crohn’s disease who responded in the induction phase, clinical and endoscopic benefits were maintained through a 44‑week maintenance period. Responders were re‑randomized to 450 mg or 900 mg subcutaneous doses every four weeks for up to 58 weeks of exposure, and these longer‑term data reinforce the earlier phase 2b induction findings showing meaningful benefit versus placebo at week 14.
Both doses were generally well tolerated. The most common adverse events (≥5%) across doses were upper respiratory tract infection, nasopharyngitis, Crohn’s disease, and hypertension, consistent with earlier results. Duvakitug preferentially blocks TL1A‑DR3 signaling (potentially reducing inflammation and fibrosis) and is now in phase 3 studies; its safety and efficacy have not yet been reviewed by regulatory authorities. Detailed results will be presented at a forthcoming medical meeting.
Read Announcement- Drug:
- duvakitug
- Announced Date:
- February 18, 2025
- Indication:
- for the treatment of moderate-to-severe inflammatory bowel disease (IBD).
Announcement
Teva Pharmaceutical announced that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO).
AI Summary
Teva Pharmaceutical Industries Ltd. announced that it will host a conference call and live webcast on Monday, February 24, 2025, at 8 am Eastern Time. During this event, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, along with external IBD key opinion leaders, will discuss the recently presented positive Phase 2b results for duvakitug (anti-TL1A). These encouraging data were shared at the 20th Annual Congress of the European Crohn’s and Colitis Organization (ECCO).
Interested participants are encouraged to register in advance to receive a local or toll-free phone number and their personal pin. A live webcast of the event will be available on Teva’s website, with a replay provided 24 hours after the call for those who are unable to attend live.
Read Announcement- Drug:
- duvakitug
- Announced Date:
- December 17, 2024
- Indication:
- for the treatment of moderate-to-severe inflammatory bowel disease (IBD).
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announce that the Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD). RELIEVE UCCD investigated duvakitug (TEV'574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for the treatment of moderate-to-severe inflammatory bowel disease (IBD).
AI Summary
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Sanofi have announced positive results from the Phase 2b RELIEVE UCCD study. This study focused on patients with moderate-to-severe inflammatory bowel disease, including both ulcerative colitis (UC) and Crohn’s disease (CD). The trial tested duvakitug (TEV'574/SAR447189), a human IgG1-λ2 monoclonal antibody designed to target TL1A. Researchers reported that the study met its primary endpoints, showing promise for the drug's ability to address key symptoms and underlying inflammation in these patients. The achievement marks an important step forward in the development of new treatments for IBD, potentially offering a novel option for those who have not responded well to current therapies.
Read Announcement
Teriparatide FDA Regulatory Events
Teriparatide is a drug developed by Teva Pharmaceutical Industries for the following indication: To treat osteoporosis.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- teriparatide
- Announced Date:
- December 15, 2025
- Indication:
- To treat osteoporosis
Announcement
Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen.
AI Summary
Amphastar Pharmaceuticals announced FDA approval of its ANDA for teriparatide injection, USP 560 mcg/2.24 mL (250 mcg/mL) single‑patient‑use prefilled pen. The FDA found Amphastar’s product bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO®.
Amphastar said this is its first pen device combination product, offering an easy‑to‑use, lower‑cost option for daily osteoporosis treatment. The company stated the drug product is made entirely in‑house at its U.S. facility to support supply reliability and quality control.
Teriparatide is indicated for postmenopausal women at high risk for fracture or who cannot tolerate other therapies; to increase bone mass in men with primary or hypogonadal osteoporosis at high fracture risk; and for men and women with osteoporosis caused by long‑term glucocorticoid use.
IQVIA reported about $585 million in U.S. teriparatide sales for the 12 months ended September 30, 2025. Amphastar plans to launch its teriparatide pen by the end of the year.
Read Announcement
AUSTEDO (deutetrabenazine) FDA Regulatory Events
AUSTEDO (deutetrabenazine) is a drug developed by Teva Pharmaceutical Industries for the following indication: Tardive dyskinesia and a review of clinical outcome measures in schizophrenia.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- AUSTEDO (deutetrabenazine)
- Announced Date:
- November 7, 2025
- Indication:
- Tardive dyskinesia and a review of clinical outcome measures in schizophrenia
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry.
AI Summary
Teva announced new real-world data from the ongoing IMPACT-TD Registry at the Neuroscience Education Institute Fall Congress (Nov 6–9, 2025). The interim analysis looked at 27 adults with tardive dyskinesia who were treated with AUSTEDO or AUSTEDO XR for three months.
Participants reported meaningful improvements across daily life areas: speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). Most (85%) who took AUSTEDO or AUSTEDO XR alongside their mental health medications said their underlying mental health remained stable or improved. The mean Abnormal Involuntary Movement Scale (AIMS) motor score fell by −2.9, indicating reduced severity of involuntary movements.
The study cohort included common psychiatric comorbidities (bipolar 41%, anxiety 37%, depression 26%, schizophrenia 19%), reflecting a diverse real-world population. Teva said the findings suggest symptom reduction can improve daily function and quality of life and emphasized its commitment to supporting people living with TD.
Read Announcement- Drug:
- AUSTEDO (deutetrabenazine)
- Announced Date:
- September 20, 2025
- Indication:
- Tardive dyskinesia and a review of clinical outcome measures in schizophrenia
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR.
AI Summary
Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced real-world survey results for AUSTEDO XR® (deutetrabenazine) extended-release tablets in adults with tardive dyskinesia. The noninterventional survey included 209 patients, and more than 94% reported that their uncontrollable movements improved after starting AUSTEDO XR.
Over 77% of participants said movement reduction led to greater comfort in social settings and better emotional well-being. More than 89% expressed overall satisfaction with AUSTEDO XR, and 96% were interested in continuing treatment. Almost all patients (over 96%) found the once-daily tablets easy to take, and at least 82% appreciated having their dose adjusted by a healthcare provider.
Presented at the 2025 Psych Congress Annual Meeting, these findings highlight how AUSTEDO XR can reduce motor symptoms and support improved quality of life for people living with tardive dyskinesia.
Read Announcement
Saxenda FDA Regulatory Events
Saxenda is a drug developed by Teva Pharmaceutical Industries for the following indication: for Weight Loss.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Saxenda
- Announced Date:
- August 28, 2025
- Indication:
- for Weight Loss
Announcement
Teva Pharmaceuticals announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection).
AI Summary
Teva Pharmaceuticals announced today that the U.S. Food and Drug Administration approved and Teva launched a generic version of Saxenda® (liraglutide injection). It is the first-ever generic glucagon-like peptide-1 (GLP-1) therapy approved specifically for weight loss in the U.S. and comes as demand for GLP-1 drugs continues to rise.
Liraglutide injection is indicated for adults with obesity or overweight who have weight-related health issues and pediatric patients aged 12 to 17 who weigh over 60 kg. When used alongside a reduced-calorie diet and increased physical activity, it helps patients lose weight. Saxenda® had annual sales of $165 million as of June 2025.
This approval and launch underscore Teva’s Pivot to Growth Strategy and support its complex generics portfolio. As the fifth first-to-market generic Teva has introduced this year, the product highlights Teva’s ongoing commitment to expand affordable, high-quality treatment options for patients.
Read Announcement
AJOVY (Fremanezumab-vfrm) FDA Regulatory Events
AJOVY (Fremanezumab-vfrm) is a drug developed by Teva Pharmaceutical Industries for the following indication: Comorbid depression, anxiety or hypertension, as well as migraine.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- AJOVY (Fremanezumab-vfrm)
- Announced Date:
- August 6, 2025
- Indication:
- Comorbid depression, anxiety or hypertension, as well as migraine
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more.
AI Summary
Teva Pharmaceuticals announced that the U.S. Food and Drug Administration has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for pediatric migraine prevention as well as adult migraine prevention.
The medication is administered once a month and can be given in a healthcare setting or at home by a patient or caregiver. Preventive use of AJOVY aims to reduce the frequency and severity of migraine attacks, helping young patients better manage school, social activities, and daily routines. Monthly dosing is designed to support adherence and lower the treatment burden for families.
Building on its initial adult approval in 2018, this expanded pediatric indication underscores Teva’s commitment to advancing neurological therapies. It fills a long-standing gap in care by offering a new preventive option to improve quality of life and reduce school absences for children and teens living with migraine.
Read Announcement
Risperidone FDA Regulatory Timeline and Events
Risperidone is a drug developed by Teva Pharmaceutical Industries for the following indication: Injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- risperidone
- Announced Date:
- May 30, 2025
- Indication:
- Injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults
Announcement
Teva Pharmaceuticals announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, versus second-generation daily oral options.
AI Summary
Teva Pharmaceuticals has presented new real-world data evaluating UZEDY® (risperidone) extended‐release injectable suspension, which is used every one or two months in adults with schizophrenia. The study compared UZEDY with daily oral second-generation antipsychotic options and found that patients on UZEDY experienced fewer relapses and a longer time before a relapse occurred. Additionally, these patients showed improved adherence and persistence with their treatment regimen.
The findings also revealed that UZEDY users had fewer inpatient hospital stays, outpatient visits, and emergency department trips, resulting in lower overall healthcare resource utilization. This data suggests that UZEDY could offer a more effective treatment alternative for individuals who have difficulty following daily medication schedules, possibly reducing hospital visits and overall healthcare costs.
Read Announcement- Drug:
- risperidone
- Announced Date:
- February 25, 2025
- Indication:
- Injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).
AI Summary
Teva Pharmaceuticals announced that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of bipolar I disorder (BP-I) in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA). This filing leverages existing clinical data from prior risperidone formulations and builds on the Agency’s previous findings related to safety and efficacy. The submission marks an important step toward expanding UZEDY’s potential beyond its current approval for treating schizophrenia, and it demonstrates Teva’s commitment to addressing the unmet needs of patients with BP-I. Teva will lead the regulatory process, and Medincell is eligible for royalties on net sales, underscoring the collaborative effort to provide new long-acting injectable options that may help improve treatment adherence and enhance the management of complex mental health conditions.
Read Announcement- Drug:
- risperidone
- Announced Date:
- September 23, 2024
- Indication:
- Injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults
Announcement
Teva Pharmaceuticals today presented data informing clinical strategies for switching patients to UZEDY®, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly subcutaneous injection of Perseris® (RBP-7000).
AI Summary
Teva Pharmaceuticals recently presented new data that guides how to switch patients with schizophrenia from a once‐monthly subcutaneous injection of Perseris® (RBP‑7000) to UZEDY®, an extended‑release injectable suspension of risperidone. UZEDY® is designed to be administered subcutaneously every one or two months, potentially offering a more convenient treatment schedule. This study outlines practical clinical strategies that can help doctors transition patients smoothly to UZEDY®, aiming to maintain consistent therapeutic effects while reducing injection frequency. The data provide insights into dosing and administration techniques that may enhance patient adherence and overall comfort with treatment. Teva’s findings contribute to the understanding of how different injection schedules can be used effectively, which might improve long‑term management of schizophrenia. Additional studies and further clinical discussions are expected to continue refining these treatment approaches.
Read Announcement- Drug:
- risperidone
- Announced Date:
- June 1, 2024
- Indication:
- Injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program.
AI Summary
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., recently presented seven studies from its long-acting injectable (LAI) schizophrenia research program. The studies offer new insights into switching patients from a once-monthly intramuscular injection of paliperidone palmitate to UZEDY, a subcutaneous formulation of risperidone. According to the population pharmacokinetic analysis, switching to UZEDY four weeks after the last dose of paliperidone palmitate provides a comparable profile, with similar active moiety levels. UZEDY is designed to be administered every one or two months, without requiring an initial loading dose or oral supplementation. The findings address a current gap in clinical data regarding transitions between LAI options. These insights are expected to help healthcare providers optimize treatment strategies for schizophrenia patients and were presented at the Psych Congress Elevate 2024 Annual Meeting in Las Vegas.
Read Announcement
TEV-53408 FDA Regulatory Events
TEV-53408 is a drug developed by Teva Pharmaceutical Industries for the following indication: In adults with celiac disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- TEV-53408
- Announced Date:
- May 27, 2025
- Indication:
- In adults with celiac disease
Announcement
Teva Pharmaceutical announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet.
Read Announcement
AJOVY® (fremanezumab) FDA Regulatory Events
AJOVY® (fremanezumab) is a drug developed by Teva Pharmaceutical Industries for the following indication: For Episodic Migraine in Children.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- AJOVY® (fremanezumab)
- Announced Date:
- April 7, 2025
- Indication:
- For Episodic Migraine in Children
Announcement
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more.
AI Summary
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm). The application seeks to expand the drug’s use to include the prevention of episodic migraine in children and adolescents aged 6-17 years who weigh at least 45 kilograms (99 pounds).
If approved, AJOVY will become the first calcitonin gene-related peptide (CGRP) antagonist available for migraine prevention in both adults and pediatric patients. The move addresses a significant unmet need for effective migraine treatments in younger populations. Positive results from the Phase 3 SPACE trial, demonstrating substantial reductions in monthly migraine and headache days along with a consistent safety profile, support the application. This development reflects Teva’s ongoing commitment to expanding access to innovative treatments for diverse patient groups.
Read Announcement- Drug:
- AJOVY® (fremanezumab)
- Announced Date:
- December 4, 2024
- Indication:
- For Episodic Migraine in Children
Announcement
Teva Pharmaceutical presented positive data from its Phase 3 SPACE study evaluating the efficacy and safety of AJOVY® (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years.1
AI Summary
Teva Pharmaceutical Industries recently presented positive results from its Phase 3 SPACE study evaluating AJOVY® (fremanezumab) for preventing episodic migraine in children and adolescents aged 6-17 years. The trial demonstrated that AJOVY significantly reduced monthly migraine days and monthly headache days compared to placebo over a 12-week period. Results showed a reduction of 2.5 monthly migraine days in the AJOVY group compared to 1.4 in the placebo group, and 2.6 versus 1.5 monthly headache days, with a higher percentage of patients achieving a 50% response rate.
The study confirmed that the efficacy and safety profile seen in adults also applies to the pediatric population, with consistent benefits across different age groups and sexes. No new safety concerns were observed, marking AJOVY as a promising treatment option for young patients with episodic migraine. This milestone provides hope for improved care for children and adolescents facing the challenges of migraine.
Read Announcement
TVB-009P FDA Regulatory Events
TVB-009P is a drug developed by Teva Pharmaceutical Industries for the following indication: For postmenopausal osteoporosis.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- TVB-009P
- Announced Date:
- October 8, 2024
- Indication:
- For postmenopausal osteoporosis.
Announcement
Teva Pharmaceutical Industries Ltd. announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab).1
AI Summary
Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has accepted and the European Medicines Agency (EMA) has validated its applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab). The U.S. Biologics License Application (BLA) seeks to establish interchangeability, while the European Marketing Authorization Application (MAA) covers all indications approved for Prolia, including treatment for conditions that increase fracture risk, such as postmenopausal osteoporosis. The submissions are supported by comprehensive analytical and clinical data, including results from a Phase 3 trial that compared TVB-009P with Prolia in women with postmenopausal osteoporosis. Both agencies are expected to deliver their decisions or opinions during the second half of 2025. This move marks an important step for Teva’s expanding biosimilar portfolio, reinforcing its commitment to providing more accessible treatment options for patients globally.
Read Announcement
